NEW YORK--(BUSINESS WIRE)--

Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that the Company will present at the LD Micro Conference on Tuesday, April 29th at 5:00 PM PDT. Senior Vice President Corporate Development, William Prather RPh, MD, will represent the Company. The conference will be held at the Omni Los Angeles Hotel in Los Angeles, California.

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on selected names throughout the year.

Mr. Zami Aberman, Pluristem's President & CEO, stated: "We are pleased that LD MICRO has invited us to this prestigious conference, which allows us to present Pluristem's unique and innovative cellular therapeutics business model to the investment community. Pluristem has recently announced pre-clinical data that shows potential of our PLX (Placental eXpanded) cells to be therapeutically beneficial to millions of Stroke and MS patients, in addition to those suffering from Peripheral Artery Disease or in need of Bone Marrow Transplantation. This data represents the ability of these cells to become a most promising product of the 21st century."

For information on the list of presenting companies or to register for the event, please visit http://ldmicro.com or call 310-862-4512.

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental mesenchymal stromal cells (MSCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include the PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; the PLX-STROKE, targeting ischemic stroke victims; and the PLX-MS, targeting Multiple Sclerosis.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

    See our product animation on YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. For example, when we say that our recently announced pre-clinical data shows potential of our PLX (Placental eXpanded) cells to be therapeutically beneficial to millions of Stroke and MS patients, in addition to those suffering from Peripheral Artery Disease or in need of Bone Marrow Transplantation; that this data represents the ability of these cells to become a most promising product of the 21st century; we are using forward-looking statements. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Source: Pluristem Therapeutics Inc.